Bioasis Announces Publication of CNS Delivery of siRNA via xB³ ™ Platform Technology

Rhea-AI Summary

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) announced a significant milestone on March 29, 2021, with the publication of research validating its xB³™ platform for delivering siRNA across the blood-brain barrier (BBB). Conducted by Bioasis scientists and Dr. Wilfred A. Jefferies, the study demonstrated that the xB³™ platform can effectively deliver therapeutic doses, reducing stroke damage and enhancing neurological function in an ischemic stroke model. This research supports Bioasis’s ongoing mission to develop treatments for CNS disorders, particularly in areas with high unmet medical needs.

Positive

• Publication of research validating xB³™ platform for siRNA delivery across BBB.
• Demonstrated effective therapeutic knockdown of NOX4 gene related to ischemic stroke.
• Reduction in stroke damage and improvement in neurological functions in study.
• Potential for xB³™ platform to address various CNS disorders.

Negative

• None.

NEW HAVEN, Conn., March 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB³ ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the publication of research validating the ability of the company’s xB³ ™ platform to efficiently deliver siRNA across the blood-brain barrier to the central nervous system in therapeutically relevant doses.

Scientists from Bioasis and Dr. Wilfred A. Jefferies evaluated Bioasis’ xB³ ™ platform technology by investigating its application to siRNA brain delivery; this was followed by an efficacy study in an ischemic stroke model induced by transient middle cerebral artery occlusion. This research shows that the xB³ ™ platform can act as a delivery vector to facilitate BBB translocation of siRNA; where the siRNA targeting NOX4, a gene thought to be responsible for oxidative stress in ischemic stroke, can elicit effective therapeutic knockdown of a gene in the CNS. The successful delivery was demonstrated by reduced stroke damage in the brain and improved neurological function. The research conducted by Eyford, et al., “A Nanomule Peptide Carrier Delivers siRNA Across the Intact Blood-Brain Barrier to Attenuate Ischemic Stroke,” was published in the Frontiers in Molecular Biosciences.

The data presented in this publication provide evidence for the utility of xB³ ™ peptide (previously known as MTfpep) as a platform technology for delivery of recombinant and chemically conjugated drug across the BBB. This study demonstrates both siRNA-carrier delivery and therapeutic efficacy in CNS disease model where the BBB remains intact and thus offers new avenues for potential siRNA focused treatments in variety of neuropathologies that are currently refractory to existing therapies.

Dr. Wilfred A. Jefferies, Professor at University of British Columbia, stated, “This study demonstrates for the first time, the translocation of a small peptide, nanomule, across the intact blood brain barrier carrying a payload sufficient to modify a disease in the central nervous system, in this case an siRNA that ameliorates ischemic stroke. The implications of this discovery are wide ranging, and this platform may provide a general method to intervene in diseases of the brain."

“The results from this research collaboration further validates the utility of our xB³ ™ platform technology to achieve delivery of therapeutic compounds including siRNA across the BBB at levels that may help treat a variety of CNS diseases. This data is consistent with the previous studies where our technology successfully delivered antibodies and enzymes across the BBB with demonstrated efficacy in both the brain and the periphery in settings as diverse as brain cancers, neuropathic pain and lysosomal storage disorders” said Dr. Deborah Rathjen, Executive Chair of the Board, Bioasis.

On behalf of the Board of Directors of Bioasis Technologies Inc.

Deborah Rathjen, Ph.D.
Executive Chair of the Board
deborah@bioasis.us
+1.203.533.7082

Follow on:
Facebook
Instagram
LinkedIn
Twitter

BTI-CRP

About Bioasis

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB³ ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit www.bioasis.us.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact along with other statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FAQ

What is the significance of Bioasis Technologies' recent research publication?

The research publication validates Bioasis's xB³™ platform for effective siRNA delivery across the blood-brain barrier, indicating potential for new CNS disorder treatments.

How does the xB³™ platform work?

The xB³™ platform acts as a delivery vector that facilitates the translocation of siRNA across the blood-brain barrier, demonstrating efficacy in CNS disease models.

What conditions could be treated using the xB³™ platform?

The platform targets various CNS disorders, including brain cancers and neurodegenerative diseases, by delivering therapeutics across the blood-brain barrier.

What were the outcomes of the ischemic stroke model study using the xB³™ platform?

The study showed reduced stroke damage and improved neurological function, validating the platform's therapeutic potential.

What does the research imply for future CNS treatments?

The findings suggest that the xB³™ platform could lead to effective siRNA-based treatments for neuropathologies resistant to current therapies.